Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s Velcade are the cornerstones of therapy for multiple myeloma. Successive label expansions have driven significant commercial reward for some well-entrenched current therapies. Emerging agents such as AbbVie/Roche/Genentech’s Venclexta/Venclyxto, and Karyopharm Therapeutics’ selinexor are pursuing initial approvals for the treatment of multiple myeloma. This highlights the fact that untapped clinical and commercial potential remains in multiple myeloma for therapies with improved efficacy, novel mechanisms of actions, and for agents positioned in patient segments that are currently underserved.
- Revlimid and Velcade are widely used for the current treatment of multiple myeloma, but how will the use of these agents change over the forecast period? What impact will generic entries of these pivotal agents have on the myeloma market?
- How has the approval of Janssen’s Darzelex and Bristol-Myers Squibb/AbbVie’s Empliciti impacted the multiple myeloma market? How important will these agents become over the forecast period?
- What are though leaders’ opinions on agents in Phase III development for multiple myeloma, such as Merck & Co’s Keytruda, Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo, Sanofi/ImmunoGen’s isatuximab, and PharmaMar/Chugai Pharmaceutical’s Aplidin? What impact will these agents have on the multiple myeloma market?
- What are the market drivers and constraints in the multiple myeloma market, and how will the market evolve over the forecast period?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.